CVRx's Landmark Heart Failure Trial Begins Enrollment, Targeting 3x Market Expansion for Barostim
CVRX sits 81% above its 52-week low of $4.299.
Summary
CVRx announced the enrollment of the first patient in its BENEFIT-HF trial, a landmark heart failure study evaluating its Barostim therapy. This follows the company's previous disclosure in its 10-K regarding the launch of a major clinical trial aimed at substantial market expansion. The BENEFIT-HF trial is expected to be one of the largest therapeutic cardiac device trials ever for heart failure, enrolling 2,500 patients. If successful, the trial could expand the indicated patient population for Barostim by approximately three times, representing a highly material increase in the addressable market for this small-cap medical device company. Investors will monitor future enrollment milestones and eventual trial results, though the trial is expected to continue through 2032.
At the time of this announcement, CVRX was trading at $7.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $206M. The 52-week trading range was $4.30 to $11.30. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.